BioSpace News Archive

The Janssen Pharmaceutical Companies of Johnson & Johnson announced data from the Phase 2a IRIS-RA clinical study for the treatment of adults living with moderate to severe active rheumatoid arthritis who have tested positive for anti-citrullinated protein antibodies a and/or rheumatoid factor, and who have had an inadequate response or intolerance to at least one anti-tumor necrosis factor therapy.

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, announced an agreement with India-based Spinco Biotech to further extend its reach in Asia.

Immunovia, the diagnostics company focused on early detection of pancreatic cancer, announced the successful completion of the discovery phase for the Company’s next-generation test.

Amytrx Therapeutics, a leading biopharmaceutical company specializing in the development of novel therapies for dermatology and inflammation, is pleased to announce the addition of two distinguished scientists to its Board of Directors.

Medline announced it has entered into a multi-year prime vendor distribution agreement with University of Utah Health, a healthcare provider for the people of Utah, Idaho, Wyoming, Montana, western Colorado, and much of Nevada and the only academic medical center in the Mountain West.

The shareholders in Medivir AB reg. no. 556238-4361 are hereby convened to the extraordinary general meeting, which will be held on Friday 1 December 2023, at 10.00 CET at Helio GT30, Grev Turegatan 30, Stockholm, Sweden.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, reported its financial results for the quarter ended September 30, 2023, and provided a corporate update.

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel multifunctional biotherapeutics, today reported financial results for the three and nine months ended September 30, 2023 and provided a summary of recent business highlights.

Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T‑cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the third quarter ended September 30, 2023.

TFF Pharmaceuticals, Inc. announced that management will host a conference call to discuss the financial results for the third quarter of 2023 and provide an update on recent corporate and clinical developments on Tuesday, November 14, 2023, at 4:30 PM ET.